![John Michael Preston](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Michael Preston
Keine laufenden Positionen mehr
Profil
John Michael Preston served as Chairman at Velcera LLC.
He holds a doctorate degree from the University of Glasgow and another doctorate degree from the London School of Hygiene & Tropical Medicine.
Ehemalige bekannte Positionen von John Michael Preston
Unternehmen | Position | Ende |
---|---|---|
Velcera LLC
![]() Velcera LLC Pharmaceuticals: MajorHealth Technology Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA. | Vorsitzender | - |
Ausbildung von John Michael Preston
University of Glasgow | Doctorate Degree |
London School of Hygiene & Tropical Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Velcera LLC
![]() Velcera LLC Pharmaceuticals: MajorHealth Technology Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA. | Health Technology |